方法比较流感疫苗的有效性,以指导潜在的优惠产品建议
Edward A Belongia1, Huong Q Nguyen1, David L McClure1
1Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA.
概括
新型流感疫苗的目标是提供更广泛,更长时间的保护. 评估它们的有效性需要仔细考虑比较研究,特别是考虑到疫苗接种带来的挑战.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 公共卫生 公共卫生
背景情况:
- 预计将有新的流感疫苗,旨在提高交叉反应性和保护时间.
- 目前的推依赖于有效性评估,需要新型疫苗的强有力的方法.
研究的目的:
- 讨论评估新型流感疫苗比较有效性的考虑因素.
- 突出绝对和相对疫苗有效性 (rVE) 评估的重要性.
主要方法:
- 审查评估疫苗有效性的方法,包括临床试验,集群随机试验和观察设计.
- 讨论不同的研究设计对rVE的优点和局限性.
主要成果:
- 集群随机试验可以减少偏见,但面临着运营方面的挑战.
- 观察性研究提供了及时和具有成本效益的rVE数据,但与可变的疫苗接种斗争.
结论:
- 比较有效性评估对于为新型流感疫苗的建议提供信息至关重要.
- 解决评估rVE的挑战,特别是可变的吸收,对于现实世界的应用至关重要.
相关概念视频
Vaccinations
51.2K
Overview
51.2K
Pharmacokinetic Models: Comparison and Selection Criterion
334
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
334
Bioequivalence Data: Statistical Interpretation
194
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
194
Bioequivalence studies: Biowaivers
225
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
225
Bioequivalence: Overview
1.8K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.8K


